Cathie Wood’s Ark Invest increased its exposure to AI infrastructure, digital platforms, and biotechnology, led by purchases ...
As AI companies warn of the dangers of self-improving AI, a new report offers a rare look at how they’re working to make it a ...
Recursion (RXRX) stock dips after $200M equity offering despite Sanofi (SNY) choosing its first AI drug candidate under a ...
Recursion Pharma launches a $200M equity offering and reports a Sanofi milestone but is rated a Hold on limited near-term ...
Since I called it three times in the recursion, the return process also happens three times. Even though I understood it in ...
Recursion Pharmaceuticals (RXRX) closed at $4.05 in the latest trading session, marking a +2.02% move from the prior day. Elsewhere, the Dow saw a downswing of 0.36%, while the tech-heavy Nasdaq ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) snapped a three-day winning streak on Thursday, surging as much as 17.9 percent ...
There has been another major milestone in the field of AI-driven drug discovery (AI drug discovery).I would like to organize ...
Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other prominent healthcare specialists and mutual funds invest ...
Google open-sourced Harness2, a recursive agent harnessing framework that lifted GLM-5 11.5 points on WorkBuddy-Bench with ...
Recursion Pharmaceuticals Inc. announced Thursday that Sanofi has selected the first development candidate under their research collaboration, triggering a $10 million milestone p ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results